STOCK TITAN
  1. Home
  2. News
  3. AIM

AIM ImmunoTech Inc - AIM STOCK NEWS

Welcome to our dedicated news page for AIM ImmunoTech (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIM ImmunoTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIM ImmunoTech's position in the market.

News
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need by Thomas Equels, the Chief Executive Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Rhea-AI Summary
AIM ImmunoTech appoints Dr. Charles Lapp as Consulting Medical Officer for ME/CFS and Long COVID Programs, aiming to develop Ampligen as a potential treatment. Dr. Lapp's expertise and dedication to FDA approval are highlighted, with CEO Equels praising his contribution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.59%
Tags
covid-19
-
News
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment discussing the potential synergistic effect of combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer, indicating promising results for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
none
News
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Rhea-AI Summary
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased anti-tumor immunity, indicating potential for broader application across various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.96%
Tags
none
-
News
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
AIM ImmunoTech Inc. reports financial results for 2023, highlighting positive data and milestones achieved in various clinical studies. The company aims to create stockholder value through operational, clinical, and regulatory initiatives. Key highlights include positive findings in treating pancreatic cancer and Post-COVID fatigue, as well as bolstering intellectual property. Financially, the company reported $13.1 million in cash and investments, with increased R&D and administrative expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
earnings
-
News
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Rhea-AI Summary
AIM ImmunoTech Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3rd, 2024. Thomas K. Equels, CEO, will discuss company updates and meet with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
conferences
News
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
Rhea-AI Summary
AIM ImmunoTech Inc. to discuss Q4/FY2023 results in a conference call on April 2, 2024, led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
earnings
-
News
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive data analysis from a study on Ampligen in treating advanced pancreatic cancer. The study shows immune-stimulatory properties of TLR-3 activation, enhancing anti-tumor immunity through dendritic cell-mediated T cell responses. Ampligen treatment correlates with improved clinical outcomes and decreased expression of immune checkpoints. The company aims to expand Ampligen's application to various solid tumor types, with ongoing clinical trials to evaluate its effectiveness in pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
News
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment featuring Thomas Equels, discussing corporate overview, business outlook, and the AIM opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.46%
Tags
none
News
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
AIM ImmunoTech Inc. releases CEO Corner segment discussing Advanced Recurrent Ovarian Cancer and clinical development milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
Stock AIM logo
AIM ImmunoTech Inc

NYSE:AIM

AIM Rankings

#5102 Ranked by Market Cap
#3581 Ranked by Stock Gains
N/A Ranked by Dividends

AIM Stock Data

24.71M
45.42M
8.99%
8.32%
0.99%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Ocala

About AIM

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as